Qiagen Details Role of Recent Acquisitions, Agreements in Molecular Dx Business

Qiagen this week updated investors on how its recent spate of acquisitions, licensing agreements, and partnerships will drive organic growth in its sample preparation and PCR-based molecular diagnostics business.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.